Literatur
- 1
O’Sullivan S S, Evans A H, Lees A J.
Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.
CNS Drugs.
2009;
23
157-170
- 2
Barns Neurauter M P, Rickards H, Cavanna A E.
The prevalence and clinical characteristics of pathological gambling in Parkonson’s
disease: an evidence-based review.
Funct Neurol.
2010;
25
9-13
- 3
Cornelius J R, Tippmann-Peikert M, Slocumb N L et al.
Impulse control disorders with the use of dopaminergic agents in restless-legs syndrome:
a case-control study.
Sleep.
2010;
33
81-87
- 4
Gahr M, Connemann B J, Schönfeldt-Lecuona C J.
Dopaminergika-induziertes pathologisches Glücksspiel.
Fortschr Neurol Psychiat.
2011;
79
dieses Heft
- 5
Davie M.
Pathological gambling associated with cabergoline.
J Neuropsychiatr Clin Neurosci.
2007;
19
473-474
- 6
Falhammar H, Yarker J.
Pathological gambling and hypersexuality in cabergoline-treated prolactinoma.
MJA.
2009;
190
97
- 7
Alexander W H, Brown J W.
Computational models of performance monitoring and cognitive control.
Topics in Cognitive Science.
2010;
1
1-20
- 8
Frank J M, Seeberger L C, O’Reilly R C.
By carrot or by stick: cognitive reinforcement learning in parkisnonism.
Science.
2004;
306
1940-1943
- 9 Marsden C D. Discussion remark. In: Ciba Foundation Symposium 107: Functions of
the basal ganglia. London: Pitman; 1984: 219
- 10
Weintraub D, Siderow A, Potenza M et al.
Association of dopamine agonist use with impulse control disorders in Parkinson’s
disease.
Arch Neurol.
2006;
63
969-973
- 11
Weintraub D.
Impulse control disorders in Parkinson’s disease: prevalence and possible risk factors.
Parkinsonism Relat Disord.
2009;
15 (Suppl 3)
S110-S113
- 12
Thomas A, Bonanni L, Gambit F et al.
Pathological gambling in Parkinson’s disease is reduced by amantadine.
Ann Neurol.
2010;
68
400-404
Prof. Claus-Werner Wallesch
Klinik für Neurologische Rehabilitation, BDH-Klinik Elzach GmbH
Am Tannwald 1
79215 Elzach
Email: cwallesch@neuroklinik-elzach.de
